(S)-3-(4-(3-aminopyrrolidin-1-yl)-5-(7-fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-3-yl)-5-fluorobenzonitrile

ID: ALA5174433

Chembl Id: CHEMBL5174433

PubChem CID: 139392666

Max Phase: Preclinical

Molecular Formula: C24H20F2N6

Molecular Weight: 430.46

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1ccc(F)c2[nH]c(-c3cncc(-c4cc(F)cc(C#N)c4)c3N3CC[C@H](N)C3)nc12

Standard InChI:  InChI=1S/C24H20F2N6/c1-13-2-3-20(26)22-21(13)30-24(31-22)19-11-29-10-18(23(19)32-5-4-17(28)12-32)15-6-14(9-27)7-16(25)8-15/h2-3,6-8,10-11,17H,4-5,12,28H2,1H3,(H,30,31)/t17-/m0/s1

Standard InChI Key:  UJNUFHFWKHCQNO-KRWDZBQOSA-N

Alternative Forms

  1. Parent:

    ALA5174433

    ---

Associated Targets(Human)

SSTR5 Tclin Somatostatin receptor 5 (1477 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SSTR1 Tclin Somatostatin receptor 1 (861 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SSTR2 Tclin Somatostatin receptor 2 (1526 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SSTR3 Tclin Somatostatin receptor 3 (1562 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SSTR4 Tclin Somatostatin receptor 4 (1125 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KCNH2 Tclin HERG (29587 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP2D6 Tclin Cytochrome P450 2D6 (33882 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP3A4 Tclin Cytochrome P450 3A4 (53859 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Sstr2 Somatostatin receptor 2 (164 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 430.46Molecular Weight (Monoisotopic): 430.1718AlogP: 4.29#Rotatable Bonds: 3
Polar Surface Area: 94.62Molecular Species: BASEHBA: 5HBD: 2
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 10.18CX Basic pKa: 9.58CX LogP: 3.12CX LogD: 0.99
Aromatic Rings: 4Heavy Atoms: 32QED Weighted: 0.51Np Likeness Score: -1.20

References

1. Zhao J, Wang S, Hee Kim S, Han S, Rico-Bautista E, Sturchler E, Nguyen J, Tan H, Staley C, Karin Kusnetzow A, Betz SF, Johns M, Goulet L, Luo R, Fowler M, Athanacio J, Markison S, Scott Struthers R, Zhu Y..  (2022)  Discovery of 4-(3-aminopyrrolidinyl)-3-aryl-5-(benzimidazol-2-yl)-pyridines as potent and selective SST5 agonists for the treatment of congenital hyperinsulinism.,  71  [PMID:35605837] [10.1016/j.bmcl.2022.128807]

Source